Enregistré dans:
| Auteur principal: | |
|---|---|
| Format: | Artículo científico |
| Langue: | en |
| Publié: |
Sociedad Española de Farmacia Hospitalaria
2019
|
| Sujets: | |
| Accès en ligne: | https://www.redalyc.org/articulo.oa?id=365962275007 https://www.redalyc.org/journal/3659/365962275007/ https://www.redalyc.org/journal/3659/365962275007/html/ https://www.redalyc.org/journal/3659/365962275007/365962275007.epub https://www.redalyc.org/journal/3659/365962275007/movil |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|
| _version_ | 1866575586281914368 |
|---|---|
| author | Julia Sánchez-Gundín |
| author_facet | Julia Sánchez-Gundín |
| contents | Quality of life in non-metastasic colorectal cancer patients in FOLFOX or XELOX therapy Julia Sánchez-Gundín Ana María Fernández-Carballido Ana Isabel Torres-Suárez Dolores Barreda-Hernández Medicina XELOX FOLFOX Safety Quality of life Colorectal cancer Objective: To evaluate and to compare quality of life of patients with non-metastasic colorectal cancer treated either with FOLFOX or with XELOX scheme.Method: Descriptive prospective study during 24 months (October 2015-October 2017) for patients with non-metastasic colorectal cancer in chemotherapy adyuvant treatment. EORTC QLQ-C30 questionnaire was filled by patients at the beginning and at week 12 of adjuvant treatment. Variables collected: exposure (chemotherapeutic scheme administered), control (demographic data, disease data, treatment data) and response (scores obtained from the questionnaire). The data statistical analysis was carried out with the SPSS® 15.0 programme.Results: 30 patients were included. Statistically significant differences were found in emotional role item at the middle of the treatment (FOLFOX 92 points vs. XELOX 82 points; p = 0,036). Patients with FOLFOX presented a clinically relevant worsening in terms of daily activities, constipation and insomnia. Patients treated with XELOX a clinically relevant worsening in daily activities, constipation, fatigue, nausea, vomiting, anorexia and diarrhoea were observed.Conclusions: Patients with XELOX scheme referred to have worse emotionally status in the middle of the adjuvant treatment than patients treated with FOLFOX scheme and presented a worsening in items fatigue, nausea, vomiting, anorexia and diarrhoea. 2019 artículo científico 1130-6343 https://www.redalyc.org/articulo.oa?id=365962275007 https://www.redalyc.org/journal/3659/365962275007/ https://www.redalyc.org/journal/3659/365962275007/html/ https://www.redalyc.org/journal/3659/365962275007/365962275007.epub https://www.redalyc.org/journal/3659/365962275007/movil 10.7399/fh.11156 en http://www.redalyc.org/revista.oa?id=3659 Farmacia Hospitalaria application/pdf Sociedad Española de Farmacia Hospitalaria Farmacia Hospitalaria (España) Num.2 Vol.43 |
| format | Artículo científico |
| id | redalyc_365962275007 |
| language | en |
| publishDate | 2019 |
| publisher | Sociedad Española de Farmacia Hospitalaria |
| spellingShingle | Quality of life in non-metastasic colorectal cancer patients in FOLFOX or XELOX therapy Julia Sánchez-Gundín Medicina XELOX FOLFOX Safety Quality of life Colorectal cancer Quality of life in non-metastasic colorectal cancer patients in FOLFOX or XELOX therapy Julia Sánchez-Gundín Ana María Fernández-Carballido Ana Isabel Torres-Suárez Dolores Barreda-Hernández Medicina XELOX FOLFOX Safety Quality of life Colorectal cancer Objective: To evaluate and to compare quality of life of patients with non-metastasic colorectal cancer treated either with FOLFOX or with XELOX scheme.Method: Descriptive prospective study during 24 months (October 2015-October 2017) for patients with non-metastasic colorectal cancer in chemotherapy adyuvant treatment. EORTC QLQ-C30 questionnaire was filled by patients at the beginning and at week 12 of adjuvant treatment. Variables collected: exposure (chemotherapeutic scheme administered), control (demographic data, disease data, treatment data) and response (scores obtained from the questionnaire). The data statistical analysis was carried out with the SPSS® 15.0 programme.Results: 30 patients were included. Statistically significant differences were found in emotional role item at the middle of the treatment (FOLFOX 92 points vs. XELOX 82 points; p = 0,036). Patients with FOLFOX presented a clinically relevant worsening in terms of daily activities, constipation and insomnia. Patients treated with XELOX a clinically relevant worsening in daily activities, constipation, fatigue, nausea, vomiting, anorexia and diarrhoea were observed.Conclusions: Patients with XELOX scheme referred to have worse emotionally status in the middle of the adjuvant treatment than patients treated with FOLFOX scheme and presented a worsening in items fatigue, nausea, vomiting, anorexia and diarrhoea. 2019 artículo científico 1130-6343 https://www.redalyc.org/articulo.oa?id=365962275007 https://www.redalyc.org/journal/3659/365962275007/ https://www.redalyc.org/journal/3659/365962275007/html/ https://www.redalyc.org/journal/3659/365962275007/365962275007.epub https://www.redalyc.org/journal/3659/365962275007/movil 10.7399/fh.11156 en http://www.redalyc.org/revista.oa?id=3659 Farmacia Hospitalaria application/pdf Sociedad Española de Farmacia Hospitalaria Farmacia Hospitalaria (España) Num.2 Vol.43 |
| title | Quality of life in non-metastasic colorectal cancer patients in FOLFOX or XELOX therapy |
| topic | Medicina XELOX FOLFOX Safety Quality of life Colorectal cancer |
| url | https://www.redalyc.org/articulo.oa?id=365962275007 https://www.redalyc.org/journal/3659/365962275007/ https://www.redalyc.org/journal/3659/365962275007/html/ https://www.redalyc.org/journal/3659/365962275007/365962275007.epub https://www.redalyc.org/journal/3659/365962275007/movil |